We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-1.31%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.3B
AUM Growth
-$2.36B
Cap. Flow
-$405M
Cap. Flow %
-2.65%
Top 10 Hldgs %
84.69%
Holding
128
New
12
Increased
7
Reduced
17
Closed
13

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$36M
2
AKRO
Akero Therapeutics
AKRO
+$34.4M
3
VERU icon
Veru
VERU
+$23.2M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$22.8M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$21.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$311M
2
INSM icon
Insmed
INSM
+$51.2M
3
LEGN icon
Legend Biotech
LEGN
+$47.1M
4
KRYS icon
Krystal Biotech
KRYS
+$27.9M
5
PACB icon
Pacific Biosciences
PACB
+$24.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
26
Nurix Therapeutics
NRIX
$2.45B
$50.6M 0.33%
3,882,125
– –
KDNY
27
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$49.8M 0.33%
2,534,102
– –
VERV
28
DELISTED
Verve Therapeutics
VERV
$48.7M 0.32%
1,416,530
– –
IMTX icon
29
Immatics
IMTX
$1.23B
$44.2M 0.29%
4,423,731
– –
FMTX
30
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$37.6M 0.25%
1,886,760
-138,116
-7% -$1.82M
KNSA icon
31
Kiniksa Pharmaceuticals
KNSA
$6.23B
$35.9M 0.24%
2,799,577
– –
HRTX icon
32
Heron Therapeutics
HRTX
$93.4M
$34.3M 0.22%
8,131,678
– –
JBIO
33
Jade Biosciences
JBIO
$1.18B
$32.8M 0.21%
56,559
-2,584
-4% -$1.73M
TSVT
34
DELISTED
2seventy bio
TSVT
$30M 0.2%
2,062,744
– –
KRYS icon
35
Krystal Biotech
KRYS
$10.7B
$29.4M 0.19%
422,185
-385,550
-48% -$27.9M
XENE icon
36
Xenon Pharmaceuticals
XENE
$6.1B
$27.1M 0.18%
751,639
– –
CINC
37
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$26.5M 0.17%
+807,212
New +$22.8M
DBVT
38
DBV Technologies
DBVT
$813M
$25.9M 0.17%
1,461,426
– –
IDYA icon
39
IDEAYA Biosciences
IDYA
$3.43B
$24.9M 0.16%
+1,668,355
New +$21.7M
DSGN icon
40
Design Therapeutics
DSGN
$751M
$24M 0.16%
1,436,636
– –
VSTM icon
41
Verastem
VSTM
$528M
$22.9M 0.15%
2,249,075
– –
ALT icon
42
Altimmune
ALT
$568M
$22.6M 0.15%
1,769,681
-305,722
-15% -$4.51M
NVTA
43
DELISTED
Invitae Corporation
NVTA
$20.7M 0.14%
8,402,035
-1,471,453
-15% -$4.47M
BMEA icon
44
Biomea Fusion
BMEA
$88.2M
$20.6M 0.13%
2,104,559
– –
BCYC
45
Bicycle Therapeutics
BCYC
$269M
$19.6M 0.13%
+843,814
New +$20.1M
RARE icon
46
Ultragenyx Pharmaceutical
RARE
$2.46B
$19.5M 0.13%
470,974
– –
TIL icon
47
Instil Bio
TIL
$49M
$18.8M 0.12%
194,685
– –
VERU icon
48
Veru
VERU
$35.5M
$18.5M 0.12%
+160,958
New +$23.2M
RLMD icon
49
Relmada Therapeutics
RLMD
$540M
$18.3M 0.12%
495,113
– –
ALKS icon
50
Alkermes
ALKS
$8.11B
$18.2M 0.12%
815,016
-684,984
-46% -$17.8M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Baker Bros. Advisors held 128 positions worth $15.3B, down 13% from $17.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q3 2022 filing shows 12 new, 7 increased, 17 reduced and 13 closed positions. Its largest new stake was Veru: 160,958 shares worth $18.5M. The largest sale was argenx, an estimated $311M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2022 buy was Veru: 160,958 shares worth $18.5M.
  • Baker Bros. Advisors added most to Rhythm Pharmaceuticals in Q3 2022, an estimated $36M increase.
  • Baker Bros. Advisors's biggest Q3 2022 reduction was argenx, cutting an estimated $311M.
  • Baker Bros. Advisors fully exited Legend Biotech in Q3 2022, selling an estimated $47.1M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $15.3B portfolio in Q3 2022.
  • Baker Bros. Advisors opened 12 new positions and closed 13 in Q3 2022.
  • Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $15.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.